CommercialBilling CodesMedium impact
11.08.17l, Debridement of Mycotic and Symptomatic Non-Mycotic Hypertrophic Toenails
Independence Blue Cross·PA · Podiatry, Dermatology, Internal Medicine·Medical Policy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
Independence Blue Cross reissued Policy 11.08.17l with ICD-10 code updates effective 10/01/2025. Multiple sclerosis diagnosis codes were replaced with more specific subcategories (G35.A, G35.B0-B2, G35.C0-C2, G35.D), and a new Type 2 diabetes remission code (E11.A) was added. These changes affect coverage determination for mycotic and symptomatic non-mycotic hypertrophic toenail debridement in patients with qualifying systemic illnesses.
Action Required
Before 10/01/2025: Billing team must update billing system and EMR to recognize the new ICD-10 codes for multiple sclerosis (G35.A, G35.B0-B2, G35.C0-C2, G35.D) and Type 2 diabetes in remission (E11.A) as qualifying diagnoses for toenail debridement coverage under Independence Blue Cross Commercial plans. Replace the legacy G35 (Multiple sclerosis) code with the specific subcategory codes in all coverage determination logic. Verify that prior authorization workflows correctly map these new codes to the medically necessary criteria requiring active provider care documentation. Update provider and billing staff training on the new granular MS diagnosis codes. Failure to use correct ICD-10 codes may result in claim denials or payment delays for qualifying toenail debridement procedures (CPT 11720, 11721).